原始出處紀錄
Incyte 決定不繼續進行原計畫中 INCB123667 合併 bevacizumab 作為卵巢癌一線維持治療的 MAESTRA-3 第 3 期研究。此決定是基於產品組合優先順序考量,並非因任何安全性或療效發現所致。公司預期此決定不會影響其財務指引或長期展望。
incy-20261113 FALSE 0000879169 0000879169 2026-04-28 2026-04-28 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2026 INCYTE CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-12400 94-3136539 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 1801 Augustine Cut-Off Wilmington , DE 19803 (Address of principal executive offices) (Zip Code) ( 302 ) 498-6700 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report.) Check the appropriate box below if the Form 8-K fi